Exploring the Rise and Legal Challenges of Weight-Loss Drug Copycats: A Look at Ozempic, Zepbound, Wegovy, and Mounjaro

Over the past two years, there has been a surge in the demand for weight loss drugs such as Ozempic, Zepbound, Wegovy, and Mounjaro. For many individuals who had previously struggled to lose weight, these medications have proven effective, causing significant decreases on the scale. The demand for these blockbuster injections has skyrocketed, with everyone eager to acquire them.

Typically, when a product experiences such widespread popularity, it would represent a lucrative opportunity for the industry. However, due to government-granted monopolies designed to foster innovation, the pharmaceutical companies responsible for these drugs are currently the sole manufacturers.

In theory, at least. However, what if this explosive demand inadvertently led to the emergence of legal counterfeits? You may have encountered them—advertisements claiming to offer the same benefits as Ozempic. But, what distinguishes these imitators from the original product, and how legitimate are they? This episode explores a life-changing drug that is also challenging the conventional methods of pharmaceutical procurement.

This broadcast was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed, edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark serves as Planet Money’s executive producer.

Listen to the podcast for free at these links: Apple Podcasts, Spotify, NPR app or any other podcast platform.

For more Planet Money content, visit Facebook, Instagram, TikTok, and subscribe to our weekly newsletter.

Support Planet Money and gain access to bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.

Music credits: Source Audio – “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”